Verastem Inc (VSTM) 1.37 $VSTM
Verastem to Present at Upcoming Investor Conferences
BusinessWire - Wed Jun 01, 6:00AM CDT
Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced that the company will present at the following upcoming investor conferences:
VSTM: 1.37 (-0.03)
Verastem Reports First Quarter 2016 Financial Results
BusinessWire - Mon May 09, 3:05PM CDT
Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today reported financial results for the first quarter ended March 31, 2016, and also provided an overview of certain corporate developments.
VSTM: 1.37 (-0.03), MRK: 58.66 (unch)
Verastem Announces the Presentation of Clinical Data at iMig 2016
BusinessWire - Tue May 03, 8:15AM CDT
--- Results from Cohort 2 continue encouraging observations from Cohort 1 for single-agent VS-6063 in chemotherapy-naive patients as a neoadjuvant therapy -
VSTM: 1.37 (-0.03)
4 Trending Small Cap Stocks That You Need To Watch Today
ACCESSWIRE - Tue Apr 26, 7:27AM CDT
NEW YORK, NY / ACCESSWIRE / April 26, 2016 / The OTC Expert is issuing a report on four stocks that are trading with heavier than usual volume. LPTN, TLOG, HTM and VSTM are on high volume watch. Continue reading to find out why these stocks are getting so much interest today. - If you want reports on the day's hottest stocks (NYSE/Nasdaq/OTC) subscribe to our newsletter at otc-expert.com.
VSTM: 1.37 (-0.03), HTM: 0.83 (+0.01), LPTN: 1.97 (+0.02), TLOG: 0.23 (unch)
Verastem Names Gregory I. Berk, MD as Chief Medical Officer
BusinessWire - Mon Apr 18, 4:20PM CDT
Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced the appointment of Gregory I. Berk, MD as Chief Medical Officer. Dr. Berk will be responsible for leading the Company's global clinical development strategy and clinical operations. Dr. Berk replaces interim Chief Medical Officer, Lou Vaickus, MD, FACP, from aktaPD who will continue to serve Verastem as a consultant.
VSTM: 1.37 (-0.03), MRK: 58.66 (unch)
Verastem Co-Founder, Dr. Robert Weinberg, Recognized with Two Prestigious Cancer Research Awards
BusinessWire - Mon Apr 18, 6:00AM CDT
Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced that Robert Weinberg, Ph.D., Verastem Co-founder and Chairman of the Scientific Advisory Board, and a pioneer in cancer research, was recently honored with the Salk Institute Medal for Research Excellence and the 13th annual American Association of Cancer Research (AACR) Lifetime Achievement Award for Cancer Research.
VSTM: 1.37 (-0.03)
Verastem Announces Presentation of Scientific Data Supporting FAK Inhibition in Combination with Immunotherapy at the Keystone Symposium on Cancer Pathophysiology
BusinessWire - Wed Mar 30, 3:05PM CDT
Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced the oral presentation of preclinical data by the Company's scientific collaborator David G. DeNardo, PhD, Assistant Professor of Medicine, Division of Oncology, Department of Immunology, Washington University School of Medicine in St. Louis, at the Keystone Symposium on Cancer Pathophysiology being held March 28 - April 1, 2016 in Breckenridge, CO.
VSTM: 1.37 (-0.03)
Verastem Announces Oral Presentation of Data Supporting the Preferential Targeting of Ovarian Cancer Stem Cells at the Society of Gynecologic Oncology's 2016 Annual Meeting on Women's Cancer
BusinessWire - Tue Mar 22, 3:05PM CDT
Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced the presentation of scientific data at the Society of Gynecologic Oncology's 2016 Annual Meeting on Women's Cancer being held March 19-22, 2016 in San Diego, CA.
VSTM: 1.37 (-0.03)
Verastem to Present Scientific Data Supporting FAK and PI3K/mTOR Inhibition to Target Cancer Stem Cells at the Keystone Symposium on Stem Cells and Cancer
BusinessWire - Thu Mar 10, 6:00AM CST
Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced the presentation of preclinical data and participation in an expert panel at the Keystone Symposium on Stem Cells and Cancer being held March 6 - 10, 2016 in Breckenridge, CO.
VSTM: 1.37 (-0.03)
Verastem to Present at 28th Annual ROTH Conference
BusinessWire - Tue Mar 08, 6:00AM CST
Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced that the Company will present at the 28th Annual ROTH Conference on Tuesday, March 15 at 12:00 p.m. PT at the Ritz-Carlton in Dana Point, CA.
VSTM: 1.37 (-0.03)
Verastem, Inc. (NASDAQ: VSTM) Analyst Coverage Initiated
ACCESSWIRE - Mon Mar 07, 7:42AM CST
NEEDHAM, MA / ACCESSWIRE / March 7, 2016 / Verastem, Inc. (NASDAQ: VSTM) a company focused on discovering and developing drugs to treat cancer, recently reported financial results for the year ended December 31, 2015, and also provided an overview of certain corporate developments. "We are developing treatments that reduce cancer stem cells and modulate the local tumor microenvironment to allow both cancer treatments and the immune system to do their job more efficiently," said Robert Forrester, President and Chief Executive Officer of Verastem. "Our recently announced collaborations with Pfizer and Merck KGaA, and with Merck & Co. and Washington University in St. Louis, to evaluate the combination of our FAK inhibitors with immune-oncology agents speak to the understanding among the clinical community that innovative combination therapies have the potential to complement and enhance existing therapies. We begin 2016 with a strong balance sheet and expect significant progress from our ongoing programs targeting high unmet need cancers including non-small cell lung, ovarian, lymphoma, mesothelioma and pancreatic cancer. We are also planning for several trial initiations this year and we look forward to keeping you updated on our progress."
VSTM: 1.37 (-0.03), MRK: 58.66 (unch)
Verastem to Present Scientific Data Supporting FAK Inhibition in Combination with Immune Checkpoint Inhibitors at Immunotherapy World 2016
BusinessWire - Thu Jan 21, 3:05PM CST
Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced the presentation of preclinical data and participation in an expert panel at Immunotherapy World 2016 being held January 25-27, 2016 in Washington, DC.
VSTM: 1.37 (-0.03)
Former US president Jimmy Carter Says His Brain Cancer Has Disappeared
ACCESSWIRE - Wed Jan 20, 2:33PM CST
LAS VEGAS, NV / ACCESSWIRE / January 20, 2015 / Carter was given pembrolizumab, one of the most exciting new drugs in cancer treatment today. Pembrolizumab, is one of the first immunotherapy drugs. Instead of killing cancer cells, these drugs boost the immune system to do the job.
VSTM: 1.37 (-0.03)
Washington University in St. Louis Initiates Clinical Study of Verastem's VS-6063 in Combination with Merck's Pembrolizumab and Gemcitabine in Pancreatic Cancer
BusinessWire - Wed Jan 06, 6:40AM CST
Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to treat cancer, today announced the initiation of a Phase 1 dose-escalation study at Washington University to evaluate Verastem's FAK inhibitor VS-6063 in combination with Merck's PD-1 inhibitor pembrolizumab and gemcitabine in patients with pancreatic cancer. This is the first of several combination clinical trials the Company expects to initiate this year.
VSTM: 1.37 (-0.03)
Dicerna Pharmaceuticals Appoints John "Jack" Green Interim Chief Financial Officer
BusinessWire - Tue Dec 15, 5:54PM CST
Dicerna Pharmaceuticals, Inc. (NASDAQ
RNA), a leading developer of RNA interference (RNAi) therapeutics, today announced the appointment of John "Jack" Green as interim chief financial officer (CFO), effective January 1, 2016. He replaces James Dentzer, whose departure is also announced today.
VSTM: 1.37 (-0.03), DRNA: 3.21 (unch)
World Malignant Pleural Mesothelioma Therapeutics Pipeline Report H2 2015 - 32 Companies & 40 Drug Profiles
M2 - Mon Dec 14, 10:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/4n84qr/malignant_pleural) has announced the addition of the "Malignant Pleural Mesothelioma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Malignant Pleural Mesothelioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malignant Pleural Mesothelioma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Aduro BioTech, Inc. - Advantagene, Inc. - Amphera BV - AnGes MG, Inc. - ArQule, Inc. - Bayer AG - Biogen, Inc. - Bionomics Limited - Boehringer Ingelheim GmbH - Boston Biomedical, Inc. - Bristol-Myers Squibb Company - CanBas Co., Ltd. - Concordia Healthcare Corp. - EnGeneIC Ltd - F. Hoffmann-La Roche Ltd. - Five Prime Therapeutics, Inc. - Genelux Corporation - GlaxoSmithKline Plc - Juno Therapeutics Inc. - MedImmune, LLC - Merck & Co., Inc. - MolMed S.p.A. - Morphotek, Inc. - Novartis AG - Ono Pharmaceutical Co., Ltd. - Oxford BioMedica Plc - Pfizer Inc. - Pharma Mar, S.A. - Polaris Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - Verastem, Inc. - Virttu Biologics Limited Drug Profiles - Ad5-SGE-REIC/Dkk3 - amatuximab - anetumab ravtansine - ascrinvacumab - bevacizumab - BG-00001 - BMS-986148 - BNC-105 - CBP-501 - Cell Therapy 1 for Oncology - Cell Therapy for Malignant Pleural Mesothelioma and Advanced Leukemia - CRS-207 - FP-1039 - ganetespib - GEN-0101 - Gene Therapy for Malignant Pleural Mesothelioma - Gene Therapy to Activate NK4 for Malignant Pleural Mesothelioma - GLONC-1 - GSK-2256098 - HSV-1716 - iCasp9M28z - JTCR-016 - MesoCancerVac - MesoCART - Monoclonal Antibody Conjugated to Target Mesothelin for Oncology - napabucasin - NGR-hTNF - nintedanib - nivolumab - pegargiminase - pembrolizumab - porfimer sodium - rAd-IFN - Stem Cell Therapy to Target TRAIL Receptor for Malignant Pleural Mesothelioma and Metastatic Lung Cancer - TargomiRs For more information visit http://www.researchandmarkets.com/research/4n...nt_pleural
ADRO: 14.84 (+0.16), PFE: 36.78 (-0.53), ARQL: 1.68 (+0.02), BMY: 76.50 (+0.31), GSK: 45.67 (+0.42), VSTM: 1.37 (-0.03), SNTA: 0.34 (+0.07), MRK: 58.66 (unch), JUNO: 30.86 (-0.07), NVS: 83.28 (+0.21), CXRX: 17.14 (-0.31), FPRX: 51.57 (+0.88)
Relapsed Acute Myeloid Leukemia Therapeutics Pipeline Review, H2 2015
M2 - Fri Dec 11, 6:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/5bkxtd/relapsed_acute) has announced the addition of the "Relapsed Acute Myeloid Leukemia - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsed Acute Myeloid Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsed Acute Myeloid Leukemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 4SC AG - AbbVie Inc. - Actinium Pharmaceuticals, Inc. - Agios Pharmaceuticals, Inc. - Amgen Inc. - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - BioLineRx, Ltd. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Calithera Biosciences, Inc. - Celgene Corporation - Cornerstone Pharmaceuticals, Inc. - CTI BioPharma Corp. - Daiichi Sankyo Company, Limited - Eisai Co., Ltd. - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - Fujifilm Corporation - GlaxoSmithKline Plc - Igenica Biotherapeutics, Inc. - Incyte Corporation - Jiangsu Hansoh Pharmaceutical Co., Ltd. - JW Pharmaceutical Corporation - Karyopharm Therapeutics, Inc. - Kyowa Hakko Kirin Co., Ltd. - Les Laboratoires Servier SAS - MacroGenics, Inc. - Merck & Co., Inc. - Novartis AG - Polaris Pharmaceuticals, Inc. - Sunesis Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - Verastem, Inc. For more information visit http://www.researchandmarkets.com/research/5b...psed_acute
MGNX: 30.90 (+0.31), INCY: 90.00 (-0.21), AMGN: 174.76 (+0.60), GSK: 45.67 (+0.42), BMY: 76.50 (+0.31), CTIC: 0.34 (unch), VSTM: 1.37 (-0.03), SNTA: 0.34 (+0.07), ATNM: 1.71 (-0.07), MRK: 58.66 (unch), AZN: 33.97 (+0.13), CALA: 3.15 (-0.02), ABBV: 66.94 (+0.71), AGIO: 45.69 (+0.46), NVS: 83.28 (+0.21), KPTI: 7.23 (-0.15), EXEL: 9.28 (+0.01), CELGZ: 1.14 (-0.02)
Idera Announces Appointment of Joanna Horobin as Chief Medical Officer
GlobeNewswire - Wed Nov 18, 7:31AM CST
Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients with cancer and rare diseases, today announced the appointment of Joanna Horobin, M.B., Ch.B., as Senior Vice President, Chief Medical Officer. Dr. Horobin was most recently the Chief Medical Officer of Verastem, Inc. and previously served as Chief Executive Officer of Syndax Pharmaceuticals. Dr. Horobin's appointment with Idera will commence on November 30, 2015.
VSTM: 1.37 (-0.03), SNDX: 12.22 (-0.20), IDRA: 1.67 (-0.05)
Verastem Reports Third Quarter 2015 Financial and Corporate Results
BusinessWire - Mon Nov 09, 6:00AM CST
Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today reported financial results for the third quarter ended September 30, 2015, and also provided an overview of certain corporate developments.
VSTM: 1.37 (-0.03)
Verastem to Present at Upcoming Investor Conferences
BusinessWire - Wed Jun 01, 6:00AM CDT
Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced that the company will present at the following upcoming investor conferences:
VSTM: 1.37 (-0.03)
Verastem Reports First Quarter 2016 Financial Results
BusinessWire - Mon May 09, 3:05PM CDT
Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today reported financial results for the first quarter ended March 31, 2016, and also provided an overview of certain corporate developments.
VSTM: 1.37 (-0.03), MRK: 58.66 (unch)
Verastem Announces the Presentation of Clinical Data at iMig 2016
BusinessWire - Tue May 03, 8:15AM CDT
--- Results from Cohort 2 continue encouraging observations from Cohort 1 for single-agent VS-6063 in chemotherapy-naive patients as a neoadjuvant therapy -
VSTM: 1.37 (-0.03)
4 Trending Small Cap Stocks That You Need To Watch Today
ACCESSWIRE - Tue Apr 26, 7:27AM CDT
NEW YORK, NY / ACCESSWIRE / April 26, 2016 / The OTC Expert is issuing a report on four stocks that are trading with heavier than usual volume. LPTN, TLOG, HTM and VSTM are on high volume watch. Continue reading to find out why these stocks are getting so much interest today. - If you want reports on the day's hottest stocks (NYSE/Nasdaq/OTC) subscribe to our newsletter at otc-expert.com.
VSTM: 1.37 (-0.03), HTM: 0.83 (+0.01), LPTN: 1.97 (+0.02), TLOG: 0.23 (unch)
Verastem Names Gregory I. Berk, MD as Chief Medical Officer
BusinessWire - Mon Apr 18, 4:20PM CDT
Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced the appointment of Gregory I. Berk, MD as Chief Medical Officer. Dr. Berk will be responsible for leading the Company's global clinical development strategy and clinical operations. Dr. Berk replaces interim Chief Medical Officer, Lou Vaickus, MD, FACP, from aktaPD who will continue to serve Verastem as a consultant.
VSTM: 1.37 (-0.03), MRK: 58.66 (unch)
Verastem Co-Founder, Dr. Robert Weinberg, Recognized with Two Prestigious Cancer Research Awards
BusinessWire - Mon Apr 18, 6:00AM CDT
Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced that Robert Weinberg, Ph.D., Verastem Co-founder and Chairman of the Scientific Advisory Board, and a pioneer in cancer research, was recently honored with the Salk Institute Medal for Research Excellence and the 13th annual American Association of Cancer Research (AACR) Lifetime Achievement Award for Cancer Research.
VSTM: 1.37 (-0.03)
Verastem Announces Presentation of Scientific Data Supporting FAK Inhibition in Combination with Immunotherapy at the Keystone Symposium on Cancer Pathophysiology
BusinessWire - Wed Mar 30, 3:05PM CDT
Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced the oral presentation of preclinical data by the Company's scientific collaborator David G. DeNardo, PhD, Assistant Professor of Medicine, Division of Oncology, Department of Immunology, Washington University School of Medicine in St. Louis, at the Keystone Symposium on Cancer Pathophysiology being held March 28 - April 1, 2016 in Breckenridge, CO.
VSTM: 1.37 (-0.03)
Verastem Announces Oral Presentation of Data Supporting the Preferential Targeting of Ovarian Cancer Stem Cells at the Society of Gynecologic Oncology's 2016 Annual Meeting on Women's Cancer
BusinessWire - Tue Mar 22, 3:05PM CDT
Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced the presentation of scientific data at the Society of Gynecologic Oncology's 2016 Annual Meeting on Women's Cancer being held March 19-22, 2016 in San Diego, CA.
VSTM: 1.37 (-0.03)
Verastem to Present Scientific Data Supporting FAK and PI3K/mTOR Inhibition to Target Cancer Stem Cells at the Keystone Symposium on Stem Cells and Cancer
BusinessWire - Thu Mar 10, 6:00AM CST
Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced the presentation of preclinical data and participation in an expert panel at the Keystone Symposium on Stem Cells and Cancer being held March 6 - 10, 2016 in Breckenridge, CO.
VSTM: 1.37 (-0.03)
Verastem to Present at 28th Annual ROTH Conference
BusinessWire - Tue Mar 08, 6:00AM CST
Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced that the Company will present at the 28th Annual ROTH Conference on Tuesday, March 15 at 12:00 p.m. PT at the Ritz-Carlton in Dana Point, CA.
VSTM: 1.37 (-0.03)
Verastem, Inc. (NASDAQ: VSTM) Analyst Coverage Initiated
ACCESSWIRE - Mon Mar 07, 7:42AM CST
NEEDHAM, MA / ACCESSWIRE / March 7, 2016 / Verastem, Inc. (NASDAQ: VSTM) a company focused on discovering and developing drugs to treat cancer, recently reported financial results for the year ended December 31, 2015, and also provided an overview of certain corporate developments. "We are developing treatments that reduce cancer stem cells and modulate the local tumor microenvironment to allow both cancer treatments and the immune system to do their job more efficiently," said Robert Forrester, President and Chief Executive Officer of Verastem. "Our recently announced collaborations with Pfizer and Merck KGaA, and with Merck & Co. and Washington University in St. Louis, to evaluate the combination of our FAK inhibitors with immune-oncology agents speak to the understanding among the clinical community that innovative combination therapies have the potential to complement and enhance existing therapies. We begin 2016 with a strong balance sheet and expect significant progress from our ongoing programs targeting high unmet need cancers including non-small cell lung, ovarian, lymphoma, mesothelioma and pancreatic cancer. We are also planning for several trial initiations this year and we look forward to keeping you updated on our progress."
VSTM: 1.37 (-0.03), MRK: 58.66 (unch)
Verastem to Present Scientific Data Supporting FAK Inhibition in Combination with Immune Checkpoint Inhibitors at Immunotherapy World 2016
BusinessWire - Thu Jan 21, 3:05PM CST
Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced the presentation of preclinical data and participation in an expert panel at Immunotherapy World 2016 being held January 25-27, 2016 in Washington, DC.
VSTM: 1.37 (-0.03)
Former US president Jimmy Carter Says His Brain Cancer Has Disappeared
ACCESSWIRE - Wed Jan 20, 2:33PM CST
LAS VEGAS, NV / ACCESSWIRE / January 20, 2015 / Carter was given pembrolizumab, one of the most exciting new drugs in cancer treatment today. Pembrolizumab, is one of the first immunotherapy drugs. Instead of killing cancer cells, these drugs boost the immune system to do the job.
VSTM: 1.37 (-0.03)
Washington University in St. Louis Initiates Clinical Study of Verastem's VS-6063 in Combination with Merck's Pembrolizumab and Gemcitabine in Pancreatic Cancer
BusinessWire - Wed Jan 06, 6:40AM CST
Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to treat cancer, today announced the initiation of a Phase 1 dose-escalation study at Washington University to evaluate Verastem's FAK inhibitor VS-6063 in combination with Merck's PD-1 inhibitor pembrolizumab and gemcitabine in patients with pancreatic cancer. This is the first of several combination clinical trials the Company expects to initiate this year.
VSTM: 1.37 (-0.03)
Dicerna Pharmaceuticals Appoints John "Jack" Green Interim Chief Financial Officer
BusinessWire - Tue Dec 15, 5:54PM CST
Dicerna Pharmaceuticals, Inc. (NASDAQ
RNA), a leading developer of RNA interference (RNAi) therapeutics, today announced the appointment of John "Jack" Green as interim chief financial officer (CFO), effective January 1, 2016. He replaces James Dentzer, whose departure is also announced today. VSTM: 1.37 (-0.03), DRNA: 3.21 (unch)
World Malignant Pleural Mesothelioma Therapeutics Pipeline Report H2 2015 - 32 Companies & 40 Drug Profiles
M2 - Mon Dec 14, 10:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/4n84qr/malignant_pleural) has announced the addition of the "Malignant Pleural Mesothelioma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Malignant Pleural Mesothelioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malignant Pleural Mesothelioma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Aduro BioTech, Inc. - Advantagene, Inc. - Amphera BV - AnGes MG, Inc. - ArQule, Inc. - Bayer AG - Biogen, Inc. - Bionomics Limited - Boehringer Ingelheim GmbH - Boston Biomedical, Inc. - Bristol-Myers Squibb Company - CanBas Co., Ltd. - Concordia Healthcare Corp. - EnGeneIC Ltd - F. Hoffmann-La Roche Ltd. - Five Prime Therapeutics, Inc. - Genelux Corporation - GlaxoSmithKline Plc - Juno Therapeutics Inc. - MedImmune, LLC - Merck & Co., Inc. - MolMed S.p.A. - Morphotek, Inc. - Novartis AG - Ono Pharmaceutical Co., Ltd. - Oxford BioMedica Plc - Pfizer Inc. - Pharma Mar, S.A. - Polaris Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - Verastem, Inc. - Virttu Biologics Limited Drug Profiles - Ad5-SGE-REIC/Dkk3 - amatuximab - anetumab ravtansine - ascrinvacumab - bevacizumab - BG-00001 - BMS-986148 - BNC-105 - CBP-501 - Cell Therapy 1 for Oncology - Cell Therapy for Malignant Pleural Mesothelioma and Advanced Leukemia - CRS-207 - FP-1039 - ganetespib - GEN-0101 - Gene Therapy for Malignant Pleural Mesothelioma - Gene Therapy to Activate NK4 for Malignant Pleural Mesothelioma - GLONC-1 - GSK-2256098 - HSV-1716 - iCasp9M28z - JTCR-016 - MesoCancerVac - MesoCART - Monoclonal Antibody Conjugated to Target Mesothelin for Oncology - napabucasin - NGR-hTNF - nintedanib - nivolumab - pegargiminase - pembrolizumab - porfimer sodium - rAd-IFN - Stem Cell Therapy to Target TRAIL Receptor for Malignant Pleural Mesothelioma and Metastatic Lung Cancer - TargomiRs For more information visit http://www.researchandmarkets.com/research/4n...nt_pleural
ADRO: 14.84 (+0.16), PFE: 36.78 (-0.53), ARQL: 1.68 (+0.02), BMY: 76.50 (+0.31), GSK: 45.67 (+0.42), VSTM: 1.37 (-0.03), SNTA: 0.34 (+0.07), MRK: 58.66 (unch), JUNO: 30.86 (-0.07), NVS: 83.28 (+0.21), CXRX: 17.14 (-0.31), FPRX: 51.57 (+0.88)
Relapsed Acute Myeloid Leukemia Therapeutics Pipeline Review, H2 2015
M2 - Fri Dec 11, 6:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/5bkxtd/relapsed_acute) has announced the addition of the "Relapsed Acute Myeloid Leukemia - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsed Acute Myeloid Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsed Acute Myeloid Leukemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 4SC AG - AbbVie Inc. - Actinium Pharmaceuticals, Inc. - Agios Pharmaceuticals, Inc. - Amgen Inc. - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - BioLineRx, Ltd. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Calithera Biosciences, Inc. - Celgene Corporation - Cornerstone Pharmaceuticals, Inc. - CTI BioPharma Corp. - Daiichi Sankyo Company, Limited - Eisai Co., Ltd. - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - Fujifilm Corporation - GlaxoSmithKline Plc - Igenica Biotherapeutics, Inc. - Incyte Corporation - Jiangsu Hansoh Pharmaceutical Co., Ltd. - JW Pharmaceutical Corporation - Karyopharm Therapeutics, Inc. - Kyowa Hakko Kirin Co., Ltd. - Les Laboratoires Servier SAS - MacroGenics, Inc. - Merck & Co., Inc. - Novartis AG - Polaris Pharmaceuticals, Inc. - Sunesis Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - Verastem, Inc. For more information visit http://www.researchandmarkets.com/research/5b...psed_acute
MGNX: 30.90 (+0.31), INCY: 90.00 (-0.21), AMGN: 174.76 (+0.60), GSK: 45.67 (+0.42), BMY: 76.50 (+0.31), CTIC: 0.34 (unch), VSTM: 1.37 (-0.03), SNTA: 0.34 (+0.07), ATNM: 1.71 (-0.07), MRK: 58.66 (unch), AZN: 33.97 (+0.13), CALA: 3.15 (-0.02), ABBV: 66.94 (+0.71), AGIO: 45.69 (+0.46), NVS: 83.28 (+0.21), KPTI: 7.23 (-0.15), EXEL: 9.28 (+0.01), CELGZ: 1.14 (-0.02)
Idera Announces Appointment of Joanna Horobin as Chief Medical Officer
GlobeNewswire - Wed Nov 18, 7:31AM CST
Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients with cancer and rare diseases, today announced the appointment of Joanna Horobin, M.B., Ch.B., as Senior Vice President, Chief Medical Officer. Dr. Horobin was most recently the Chief Medical Officer of Verastem, Inc. and previously served as Chief Executive Officer of Syndax Pharmaceuticals. Dr. Horobin's appointment with Idera will commence on November 30, 2015.
VSTM: 1.37 (-0.03), SNDX: 12.22 (-0.20), IDRA: 1.67 (-0.05)
Verastem Reports Third Quarter 2015 Financial and Corporate Results
BusinessWire - Mon Nov 09, 6:00AM CST
Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today reported financial results for the third quarter ended September 30, 2015, and also provided an overview of certain corporate developments.
VSTM: 1.37 (-0.03)
